Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma

Recurrent cutaneous breast cancer is difficult to manage, with surgery, radiotherapy and systemic therapy all having their limitations. Miltefosine is a topical cytostatic agent which may provide an alternative approach in its treatment. Patients with previously treated progressive cutaneous lesions...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 1999, Vol.44, p.S29-S30
Main Authors: CLIVE, S, GARDINER, J, LEONARD, R. C. F
Format: Article
Language:English
Subjects:
Administration, Topical
Adult
Aged
Aged, 80 and over
Antineoplastic agents
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Breast Neoplasms, Male - drug therapy
Breast Neoplasms, Male - pathology
Carcinoma - drug therapy
Carcinoma - secondary
Chemotherapy
Female
Humans
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Phosphorylcholine - analogs & derivatives
Phosphorylcholine - therapeutic use
Skin Neoplasms - drug therapy
Skin Neoplasms - secondary
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recurrent cutaneous breast cancer is difficult to manage, with surgery, radiotherapy and systemic therapy all having their limitations. Miltefosine is a topical cytostatic agent which may provide an alternative approach in its treatment. Patients with previously treated progressive cutaneous lesions from breast cancer were treated with miltefosine on a named-patient compassionate supply basis. Miltefosine was applied topically to the skin at a dose of 2 drops/10 cm(2) skin area. Twenty-five patients were treated, most of whom had been heavily pre-treated. Treatment was continued for a median of 14 weeks (range 2-164). In 7 patients grade I skin toxicities were observed, and in 4 patients grade 3 local toxicities necessitated dose adjustments. A response was seen in 9 patients (1 complete response, 2 partial responses, 6 minor responses) giving a total response rate of 36%, with stable disease in 11 patients (44%) and progressive disease in 5 (20%). Those lesions which were superficial or < 2 cm in diameter were most likely to respond. Miltefosine, either used alone or in conjunction with other therapies for distant metastases, is an effective and tolerable local treatment for cutaneous breast cancer.
ISSN:0344-5704
1432-0843
DOI:10.1007/s002800051114